[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 26, 1995

Reducing the Impact of Opportunistic Infections in Patients With HIV InfectionNew Guidelines

Author Affiliations

From the National Center for Infectious Diseases (Drs Kaplan and Jaffe) and the National Center for Prevention Services (Dr Kaplan), Centers for Disease Control and Prevention, Atlanta, Ga; the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md (Dr Masur); and the Center for AIDS and STDs, University of Washington, Seattle (Dr Holmes).

JAMA. 1995;274(4):347-348. doi:10.1001/jama.1995.03530040075045
Abstract

As many as 1 million individuals in the United States are infected with the human immunodeficiency virus (HIV).1 For these persons, and especially for the approximately 250 000 who have severe immunosuppression as measured by a CD4+ lymphocyte count below 0.20×109/L (200/μL) (includes persons with [T. Green, PhD, Centers for Disease Control and Prevention (CDC), unpublished results, 1994] and without2 AIDS-defining illnesses) opportunistic infections exact a heavy toll in terms of quality and length of life. Among patients with severe immunosuppression, the cumulative risk of serious opportunistic infection has been estimated to be 33% after 1 year and 58% after 2 years.3 In addition to the morbidity and mortality associated with these opportunistic infections, treatment of these illnesses costs billions of dollars annually.

The last 5 years have witnessed a gratifying surge in our knowledge of the environmental sources of opportunistic pathogens, ways to reduce

First Page Preview View Large
First page PDF preview
First page PDF preview
×